Skip to main content

Advertisement

Log in

LINX® magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis

  • Review
  • Published:
Surgical Endoscopy Aims and scope Submit manuscript

Abstract

Background

The LINX® magnetic sphincter augmentation system (MSA) is a surgical technique with short-term evidence demonstrating efficacy in the treatment of medically refractory or chronic gastroesophageal reflux disease (GERD). Currently, the Nissen fundoplication is the gold-standard surgical treatment for GERD. We are the first to systematically review the literature and perform a meta-analysis comparing MSA to the Nissen fundoplication.

Methods

A comprehensive search of electronic databases (e.g., MEDLINE, EMBASE, SCOPUS, Web of Science and the Cochrane Library) using search terms “Gastroesophageal reflux or heartburn” and “LINX or endoluminal or magnetic” and “fundoplication or Nissen” was completed. All randomized controlled trials, non-randomized comparison study and case series with greater than 5 patients were included. Five hundred and forty-seven titles were identified through primary search, and 197 titles or abstracts were screened after removing duplicates. Meta-analysis was performed on postoperative quality of life outcomes, procedural efficacy and patient procedural satisfaction.

Results

Three primary studies identified a total of 688 patients, of whom 273 and 415 underwent Nissen fundoplication and MSA, respectively. MSA was statistically superior to LNF in preserving patient’s ability to belch (95.2 vs 65.9%, p < 0.00001) and ability to emesis (93.5 vs 49.5%, p < 0.0001). There was no statistically significant difference between MSA and LNF in gas/bloating (26.7 vs 53.4%, p = 0.06), postoperative dysphagia (33.9 vs 47.1%, p = 0.43) and proton pump inhibitor (PPI) elimination (81.4 vs 81.5%, p = 0.68).

Conclusion

Magnetic sphincter augmentation appears to be an effective treatment for GERD with short-term outcomes comparable to the more technically challenging and time-consuming Nissen fundoplication. Long-term comparative outcome data past 1 year are needed in order to further understand the efficacy of magnetic sphincter augmentation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. El-Serag HB, Sweet S, Winchester CC, Dent J (2014) Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 63:871–880

    Article  PubMed  Google Scholar 

  2. Toghanian S, Johnson DA, Stålhammar N-O, Zerbib F (2011) Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy. Clin Drug Investig 31:703–715

    Article  CAS  PubMed  Google Scholar 

  3. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG (2002) Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 97:575–583

    Article  CAS  PubMed  Google Scholar 

  4. Labenz J, Malfertheiner P (2005) Treatment of uncomplicated reflux disease. World J Gastroenterol 11:4291–4299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kinoshita Y, Ishihara S (2008) Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia. Ther Adv Gastroenterol 1:191–199

    Article  Google Scholar 

  6. Kawamura O, Hosaka H, Shimoyama Y, Kawada A, Kuribayashi S, Kusano M, Yamada M (2015) Evaluation of proton pump inhibitor-resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impedance and pH monitoring. Digestion 91:19–25

    Article  CAS  PubMed  Google Scholar 

  7. Patti MG (2016) An evidence-based approach to the treatment of gastroesophageal reflux disease. JAMA Surg 151:73–78

    Article  PubMed  Google Scholar 

  8. Lundell L, Miettinen P, Myrvold HE, Hatlebakk JG, Wallin L, Engstrom C, Julkunen R, Montgomery M, Malm A, Lind T, Walan A (2009) Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol Off Clin pract J Am Gastroenterol Assoc 7:1292–1298 (quiz 1260)

    Google Scholar 

  9. Yates RB, Oelschlager BK (2015) Surgical treatment of gastroesophageal reflux disease. Surg Clin N Am 95:527–553

    Article  PubMed  Google Scholar 

  10. Bonavina L, Saino G, Bona D, Sironi A, Lazzari V (2013) One hundred consecutive patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease: 6 years of clinical experience from a single center. J Am Coll Surg 217:577–585

    Article  PubMed  Google Scholar 

  11. Ganz RA, Edmundowicz SA, Taiganides PA, Lipham JC, Smith CD, DeVault KR, Horgan S, Jacobsen G, Luketich JD, Smith CC, Schlack-Haerer SC, Kothari SN, Dunst CM, Watson TJ, Peters J, Oelschlager BK, Perry KA, Melvin S, Bemelman WA, Smout AJ, Dunn D (2016) Long-term outcomes of patients receiving a magnetic sphincter augmentation device for gastroesophageal reflux. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 14:671–677

    Google Scholar 

  12. Saino G, Bonavina L, Lipham JC, Dunn D, Ganz RA (2015) Magnetic sphincter augmentation for gastroesophageal reflux at 5 years: final results of a pilot study show long-term acid reduction and symptom improvement. J Laparoendosc Adv Surg Tech Part A 25:787–792

    Article  Google Scholar 

  13. Lipham JC, Taiganides PA, Louie BE, Ganz RA, DeMeester TR (2015) Safety analysis of first 1000 patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease. Dis esophagus Off J Int Soc Dis Esophagus/ISDE 28:305–311

    Article  CAS  Google Scholar 

  14. Riegler M, Schoppman SF, Bonavina L, Ashton D, Horbach T, Kemen M (2015) Magnetic sphincter augmentation and fundoplication for GERD in clinical practice: one-year results of a multicenter, prospective observational study. Surg Endosc 29:1123–1129

    Article  PubMed  Google Scholar 

  15. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73:712–716

    Article  PubMed  Google Scholar 

  16. de Boer AG, Taskila T, Ojajarvi A, van Dijk FJ, Verbeek JH (2009) Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA 301:753–762

    Article  PubMed  Google Scholar 

  17. Reynolds JL, Zehetner J, Wu P, Shah S, Bildzukewicz N, Lipham JC (2015) Laparoscopic magnetic sphincter augmentation vs laparoscopic Nissen fundoplication: a matched-pair analysis of 100 patients. J Am Coll Surg 221:123–128

    Article  PubMed  Google Scholar 

  18. Louie BE, Farivar AS, Shultz D, Brennan C, Vallières E, Aye RW (2014) Short-term outcomes using magnetic sphincter augmentation versus Nissen fundoplication for medically resistant gastroesophageal reflux disease. Ann Thorac Surg 98:498–505

    Article  PubMed  Google Scholar 

  19. Sheu EG, Nau P, Nath B, Kuo B, Rattner DW (2015) A comparative trial of laparoscopic magnetic sphincter augmentation and Nissen fundoplication. Surg Endosc 29:505–509

    Article  PubMed  Google Scholar 

  20. Warren HF, Reynolds JL, Lipham JC, Zehetner J, Bildzukewicz NA, Taiganides PA, Mickley J, Aye RW, Farivar AS and Louie BE (2016) Multi-institutional outcomes using magnetic sphincter augmentation versus Nissen fundoplication for chronic gastroesophageal reflux disease. Surg Endosc 30:3289–3296

    Article  PubMed  Google Scholar 

  21. Bonavina L, DeMeester TR, Ganz RA (2012) LINX™ reflux management system: magnetic sphincter augmentation in the treatment of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol 6:667–674

    Article  CAS  PubMed  Google Scholar 

  22. Bonavina L, Saino G, Lipham JC, DeMeester TR (2013) LINX(®) reflux management system in chronic gastroesophageal reflux: a novel effective technology for restoring the natural barrier to reflux. Ther Adv Gastroenterol 6:261–268

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Noah J. Switzer.

Ethics declarations

Disclosures

Daniel Skubleny, Noah J. Switzer, Jerry Dang, Richdeep S. Gill, Xinzhe Shi, Christopher de Gara, Daniel W. Birch, Clarence Wong, Matthew M. Hutter and Shahzeer Karmali have no conflicts of interest or financial ties to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Skubleny, D., Switzer, N.J., Dang, J. et al. LINX® magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. Surg Endosc 31, 3078–3084 (2017). https://doi.org/10.1007/s00464-016-5370-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00464-016-5370-3

Keywords

Navigation